
Jörg Reinhardt to leave Bayer for Novartis
pharmafile | January 24, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | Bayer, Novartis, Reinhardt
The chairman of the Board and member of the Bayer executive council Dr Jörg Reinhard is stepping down from his post in the summer to be replaced by Prof Wolfgang Plischke.
Reinhard (pictured) will not renew his contract when it expires, and instead intends to stand for election as the new director of Novartis and designated non-executive chairman of the Board at its AGM in February – replacing Daniel Vasella – with a view to assuming office on 1 August.
Reinhardt who ends his active service with Bayer at the end of February is to be replaced by Plischke whose responsibilities currently include Technology, Innovation and Sustainability, and will take over the function of chairman at Bayer in addition to his existing duties until a successor is appointed.
Prior to his appointment to the Bayer Board in 2006, Plischke had worked in the healthcare field for 25 years, latterly as general manager of what was then the Pharmaceuticals Business Group.
“With his experience and his commitment, Jörg has played a major part in the very positive development of Bayer HealthCare in recent years,” said Bayer chief executive Marijn Dekkers. “However, we accept his decision to continue his career in his adopted country of Switzerland and wish him all the best for the future.”
Related Content

Evotec and Bayer announce new kidney disease study
Evotec and Bayer have announced the initiation of a phase 2 clinical study in kidney …

Novartis receives SMC approval for early breast cancer treatment
Novartis has announced that its treatment for early breast cancer, Kisqali (ribociclib), has received approval …

Novartis candidate for Sjögren’s disease presents positive results
Novartis has reported positive results from two phase 3 clinical trials – NEPTUNUS-1 and NEPTUNUS-2 …






